


Supplemental Table 5 – Risk of Bias Tables

Case Series	Did the study address a clearly focused issue?	Was the cohort recruited in an acceptable way?	Was the exposure accurately measured to minimise bias?	Was the outcome accurately measured to minimise bias?	Have the authors identified all important confounding factors?	Have they taken account of the confounding factors in the design and/or analysis?	Was the follow up of subjects complete enough?	Was the follow up of subjects long enough?	Do you believe the results?	10. Can the results be applied to the local population?	11. Do the results of this study fit with other available evidence?	12. What are the implications of this study for practice?	Overall
(Blin et al 2018)	Green	Orange	Green	Green	Red	Green	Green	Green	Green	Green	Green	Long term use of ranibizumab is effective.	Orange
(Brown et al 2014)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Ranibizumab in CRVO improves retinal anatomy and vision	Green
(Calugaru and Calugaru 2015)	Green	Green	Green	Green	Green	Green	Orange	Orange	Green	Green	Green	"IVB = sustained vision over 3 years"	Orange
(Campochiaro et al 2014)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Orange	Green	"LTO with ranibizumab are excellent"	Orange
(Hikichi et al 2014)	Green	Green	Green	Green	Green	Green	Green	Orange	Green	Green	Green	IVB is beneficial over 2 years	Green
(Horner et al 2020)	Green	Green	Green	Green	Red	Green	Green	Green	Green	Green	Green	Combination therapy is effective	Green
Inagaki et al 2019)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Orange	Green	"IVR + PRN gave pretty good visual outcome at month 24"	Green
(Khurana et al 2019)	Green	Green	Green	Green	Green	Green	Green	Orange	Green	Green	Green	Sustained benefits of TAE aflibercept over 2 years	Green





Cohort Studies	Were patient demographic characteristics clearly described?	Was there clear reporting of clinical information of the participants?	Were there clear criteria for inclusion in the case series?	Was the condition measured in a standard, reliable way for all participants included in the case series?	Was the intervention(s) or treatment procedure(s) clearly described?	Were the outcomes or follow up results of cases clearly reported?	Were adverse events (harms) or unanticipated events identified and described?	Was statistical analysis appropriate?	Overall
(Abdallah et al 2019)	Red	Orange	Green	Green	Green	Orange	Orange	Orange	Red
(Bajric et al 2015)	Green	Green	Green	Orange	Green	Green	Orange	Green	Green
(Blanc et al 2018)	Green	Green	Green	Green	Green	Green	Green	Green	Green
(Busch et al 2018)	Green	Green	Green	Green	Green	Green	Red	Green	Orange
(Chatziralli et al 2018)	Green	Orange	Green	Green	Green	Green	Green	Green	Green
Chatziralli et al (2017)	Green	Green	Green	Green	Green	Green	Green	Green	Green
(Chittajallu et al 2018)	Red	Orange	Green	Green	Green	Green	Green	Orange	Orange
(Costa et al 2021)	Green	Green	Green	Green	Green	Green	Orange	Green	Green
(Farinha et al 2016)	Green	Green	Green	Green	Green	Green	Orange	Green	Green

